Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go

The introduction of immune checkpoint inhibitors (ICIs) represents a key shift in the management strategy for patients with hepatocellular carcinoma (HCC). However, there is a paucity of predictive biomarkers that facilitate the identification of patients that would respond to ICI therapy. Although...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Pil Soo, Lee, Isaac Kise, Roh, Pu Reun, Kang, Min Woo, Ahn, Jaegyoon, Yoon, Seung Kew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659956/
https://www.ncbi.nlm.nih.gov/pubmed/36387149
http://dx.doi.org/10.3389/fonc.2022.1028728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659956/
https://www.ncbi.nlm.nih.gov/pubmed/36387149
http://dx.doi.org/10.3389/fonc.2022.1028728

Ejemplares similares